Mosaic ImmunoEngineering Inc.
CPMV
We are a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the treatment of cancer. We have historically advanced early-stage product candidates and we are pursuing new product candidates and platforms to build a product pipeline based on our deep understanding of immunotherapies.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$688K
▲ +25.4% YoY
Op. Margin
–
ROIC
-31.86%
▲ +17.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$32K
▲ +53.8% YoY
Op. Cash Flow (TTM)
-$32K
▲ +53.8% YoY
Net Debt
$2M
Cash & Equiv.
$151.00
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CPMV
Mosaic ImmunoEngineering (CPMV) in two numbers
Questions about Mosaic ImmunoEngineering
Does Mosaic ImmunoEngineering (CPMV) pay a dividend?
No. Mosaic ImmunoEngineering (CPMV) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 20 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in CPMV's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CPMV
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.